{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:45:39Z","timestamp":1792586739893,"version":"4.5.0"},"reference-count":53,"publisher":"MyJove Corporation","issue":"233","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70462","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:00:30Z","timestamp":1783724430000},"source":"Crossref","is-referenced-by-count":0,"title":["Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response"],"prefix":"10.3791","author":[{"given":"Lihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1515797","DOI":"10.3389\/fpubh.2025.1515797","type":"journal-article","article-title":"Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021","volume":"13","author":"Huang","year":"2025","unstructured":"Huang, X., Wu, Y., Ni, Y., Xu, H., He, Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front. Public Health. 13, 1515797 (2025).","journal-title":"Front. Public Health"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"e240115","DOI":"10.1530\/JOE-24-0115","type":"journal-article","article-title":"The role of adipose tissue dysfunction in hepatic insulin resistance and T2D","volume":"262","author":"Sancar","year":"2024","unstructured":"Sancar, G., Birkenfeld, A.L. The role of adipose tissue dysfunction in hepatic insulin resistance and T2D. J Endocrinol. 262 (3), e240115 (2024).","journal-title":"J Endocrinol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.35772\/ghmo.2023.01004","type":"journal-article","article-title":"Association of adipokines with insulin resistance and metabolic syndrome including obesity and diabetes","volume":"3","author":"Gupta","year":"2023","unstructured":"Gupta, A., Gupta, P., Singh, A.K., Gupta, V. Association of adipokines with insulin resistance and metabolic syndrome including obesity and diabetes. GHM Open. 3 (1), 7-19 (2023).","journal-title":"GHM Open"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"110691","DOI":"10.1016\/j.diabres.2023.110691","type":"journal-article","article-title":"Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions","volume":"200","author":"Garg","year":"2023","unstructured":"Garg, S. S. Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions. Diabetes Res. Clin. Pract. 200, 110691 (2023).","journal-title":"Diabetes Res. Clin. Pract"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/jdi.12801","type":"journal-article","article-title":"Failure of monotherapy in clinical practice in patients with type 2 diabetes: the Korean National Diabetes Program","volume":"9","author":"Jeon","year":"2018","unstructured":"Jeon, J.Y. et al. Failure of monotherapy in clinical practice in patients with type 2 diabetes: the Korean National Diabetes Program. J. Diabetes Investig. 9 (5), 1144-1152 (2018).","journal-title":"J. Diabetes Investig"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1185\/03007995.2010.504396","type":"journal-article","article-title":"Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice","volume":"26","author":"Nichols","year":"2010","unstructured":"Nichols, G.A., Conner, C., Brown, J.B. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr. Med. Res. Opin. 26 (9), 2127-2135 (2010).","journal-title":"Curr. Med. Res. Opin"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/biomedicines11092589","type":"journal-article","article-title":"The interplay of adipokines and pancreatic beta cells in metabolic regulation and diabetes","volume":"11","author":"Kim","year":"2023","unstructured":"Kim, J., Oh, C.M., Kim, H. The interplay of adipokines and pancreatic beta cells in metabolic regulation and diabetes. Biomedicines. 11 (9), 2589 (2023).","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","type":"journal-article","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2019","unstructured":"Zatterale, F. et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol. 10, 1607 (2019).","journal-title":"Front. Physiol"},{"issue":"17","key":"ref9","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.3390\/ijms25179391","type":"journal-article","article-title":"The impact of the endocrine and immunological function of adipose tissue on reproduction in women with obesity","volume":"25","author":"M\u0105czka","year":"2024","unstructured":"M\u0105czka, K., Stasiak, O., Przybysz, P., Grymowicz, M., Smolarczyk, R. The impact of the endocrine and immunological function of adipose tissue on reproduction in women with obesity. Int. J. Mol. Sci. 25 (17), 9391 (2024).","journal-title":"Int. J. Mol. Sci"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1002\/mco2.516","type":"journal-article","article-title":"Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions","volume":"5","author":"Zhao","year":"2024","unstructured":"Zhao, L. et al. Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions. MedComm. 5 (4), e516 (2024).","journal-title":"MedComm"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.trsl.2015.08.011","type":"journal-article","article-title":"Molecular and cellular mechanisms linking inflammation to insulin resistance and \u03b2-cell dysfunction","volume":"167","author":"Khodabandehloo","year":"2016","unstructured":"Khodabandehloo, H., Gorgani-Firuzjaee, S., Panahi, G., Meshkani, R. Molecular and cellular mechanisms linking inflammation to insulin resistance and \u03b2-cell dysfunction. Transl. Res. 167 (1), 228-256 (2016).","journal-title":"Transl. Res"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.3390\/molecules25215218","type":"journal-article","article-title":"An overview of the role of adipokines in cardiometabolic diseases","volume":"25","author":"Farkhondeh","year":"2020","unstructured":"Farkhondeh, T. et al. An overview of the role of adipokines in cardiometabolic diseases. Molecules. 25 (21), 5218 (2020).","journal-title":"Molecules"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biom15050612","type":"journal-article","article-title":"Understanding the role of adipokines in cardiometabolic dysfunction: a review of current knowledge","volume":"15","author":"Datta","year":"2025","unstructured":"Datta, S., Koka, S., Boini, K.M. Understanding the role of adipokines in cardiometabolic dysfunction: a review of current knowledge. Biomolecules. 15 (5), 612 (2025).","journal-title":"Biomolecules"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","type":"journal-article","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy, L., Isaacs, D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 4, 212283 (2015).","journal-title":"Drugs Context"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMED.S5114","type":"journal-article","article-title":"Saxagliptin: a selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus","volume":"4","author":"Shubrook","year":"2011","unstructured":"Shubrook, J., Colucci, R., Guo, A., Schwartz, F. Saxagliptin: a selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin. Med. Insights Endocrinol. Diabetes. 4, 1-12 (2011).","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"e14112","DOI":"10.1111\/eci.14112","type":"journal-article","article-title":"Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats","volume":"54","author":"Gusm\u00e3o-Nascimento","year":"2024","unstructured":"Gusm\u00e3o-Nascimento, J.W. et al. Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats. Eur. J. Clin. Invest. 54 (2), e14112 (2024).","journal-title":"Eur. J. Clin. Invest"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","type":"journal-article","article-title":"Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes","volume":"97","author":"Horowitz","year":"2012","unstructured":"Horowitz, M. et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract. 97 (2), 258-266 (2012).","journal-title":"Diabetes Res. Clin. Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s12013-025-01742-1","type":"journal-article","article-title":"The impact of liraglutide, a GLP-1 receptor agonist, on high glucose-induced inflammation, apoptosis, oxidative stress, and NLRP3 signaling","volume":"83","author":"Gokce","year":"2025","unstructured":"Gokce, M. et al. The impact of liraglutide, a GLP-1 receptor agonist, on high glucose-induced inflammation, apoptosis, oxidative stress, and NLRP3 signaling. Cell Biochem. Biophys. 83, 36190-3632 (2025).","journal-title":"Cell Biochem. Biophys"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","type":"journal-article","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","unstructured":"Guo, W., Tian, W., Lin, L., Xu, X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res. Clin. Pract. 170, 108487 (2020).","journal-title":"Diabetes Res. Clin. Pract"},{"key":"ref20","first-page":"23","type":"journal-article","article-title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus","volume":"5","author":"Kulasa","year":"2010","unstructured":"Kulasa, K., Edelman, S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 5, 23-37 (2010).","journal-title":"Core Evid"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12325-009-0030-9","type":"journal-article","article-title":"Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"26","author":"Deacon","year":"2009","unstructured":"Deacon, C.F., Holst, J.J. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv. Ther. 26, 488-499 (2009).","journal-title":"Adv. Ther"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"e32892","DOI":"10.1097\/MD.0000000000032892","type":"journal-article","article-title":"Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a systematic review and meta-analysis of 16 RCTs","volume":"102","author":"Zhao","year":"2023","unstructured":"Zhao, Y., Zhao, W., Bu, H., Toshiyoshi, M., Zhao, Y. Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a systematic review and meta-analysis of 16 RCTs. Medicine. 102 (6), e32892 (2023).","journal-title":"Medicine"},{"issue":"3","key":"ref23","first-page":"233","type":"journal-article","article-title":"Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes","volume":"57","author":"Savchenko","year":"2019","unstructured":"Savchenko, L.G. et al. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom. J. Intern. Med. 57 (3), 233-240 (2019).","journal-title":"Rom. J. Intern. Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4126995","DOI":"10.1155\/2022\/4126995","type":"journal-article","article-title":"Efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus: a randomised controlled clinical trial in Tianjin, China","volume":"2022","author":"Zhaohu","year":"2022","unstructured":"Zhaohu, H., Xiao, H., Hailin, S., Feng, H. Efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus: a randomised controlled clinical trial in Tianjin, China. J. Diabetes Res. 2022, 4126995 (2022).","journal-title":"J. Diabetes Res"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jdi.12457","type":"journal-article","article-title":"Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial","volume":"7","author":"Seino","year":"2016","unstructured":"Seino, Y. et al. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J. Diabetes Investig. 7 (4), 565-573 (2016).","journal-title":"J. Diabetes Investig"},{"key":"ref26","volume-title":"Replication of the CARMELINA diabetes trial in healthcare claims","year":"2026","unstructured":"MedDataX Team. Replication of the CARMELINA diabetes trial in healthcare claims. Available at: https:\/\/meddatax.com\/clinical-trials\/NCT03936036 Accessed: 7 April (2023).","type":"book"},{"key":"ref27","volume-title":"Targeting INflammation using SALsalate in type 2 diabetes (TINSAL-T2D)","year":"2026","unstructured":"MedDataX Team. Targeting INflammation using SALsalate in type 2 diabetes (TINSAL-T2D). Available at: https:\/\/meddatax.com\/clinical-trials\/NCT00392678 Accessed: 7 April (2026).","type":"book"},{"issue":"3","key":"ref28","first-page":"282","type":"journal-article","article-title":"Effect of dietary carbohydrate intake on glycaemic control and insulin resistance in type 2 diabetes: a systematic review and meta-analysis","volume":"34","author":"Lan","year":"2025","unstructured":"Lan, J., Chen, M., Zhang, X., Yang, J. Effect of dietary carbohydrate intake on glycaemic control and insulin resistance in type 2 diabetes: a systematic review and meta-analysis. Asia Pac. J. Clin. Nutr. 34 (3), 282-297 (2025).","journal-title":"Asia Pac. J. Clin. Nutr"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/mohe.mohe_27_22","type":"journal-article","article-title":"Sports nutritionists adopt the nutrition care process road map to develop individualized meal planning for athletes","volume":"11","author":"Mustafa","year":"2022","unstructured":"Mustafa, N. et al. Sports nutritionists adopt the nutrition care process road map to develop individualized meal planning for athletes. Malays. J. Mov. Health Exerc. 11 (2), 57 (2022).","journal-title":"Malays. J. Mov. Health Exerc"},{"key":"ref30","type":"book","volume-title":"Current utilization patterns of glucagon-like peptide-1 receptor agonists: report","author":"Vannabouathong","year":"2022","unstructured":"Vannabouathong, C., Crotty, C., Le, K., Eurich, D., Dyrda, P. Current utilization patterns of glucagon-like peptide-1 receptor agonists: report. PMID: 38696623 (2022)."},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/193229681100500644","type":"journal-article","article-title":"An analysis of dosage volume for halfway doses in the Victoza pen","volume":"5","author":"Kroon","year":"2011","unstructured":"Kroon, L. An analysis of dosage volume for halfway doses in the Victoza pen. J. Diabetes Sci. Technol. 5 (6), 1625-1626 (2011).","journal-title":"J. Diabetes Sci. Technol"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1060028017731111","type":"journal-article","article-title":"Dapagliflozin\/saxagliptin fixed-dose tablets: a new sodium-glucose cotransporter 2 and dipeptidyl peptidase 4 combination for the treatment of type 2 diabetes","volume":"52","author":"Coppenrath","year":"2018","unstructured":"Coppenrath, V.A., Hydery, T. Dapagliflozin\/saxagliptin fixed-dose tablets: a new sodium-glucose cotransporter 2 and dipeptidyl peptidase 4 combination for the treatment of type 2 diabetes. Ann. Pharmacother. 52 (1), 78-85 (2018).","journal-title":"Ann. Pharmacother"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/aogs.14366","type":"journal-article","article-title":"Current controversies: null hypothesis significance testing","volume":"101","author":"Sedgwick","year":"2022","unstructured":"Sedgwick, P.M., Hammer, A., Kesmodel, U.S., Pedersen, L.H. Current controversies: null hypothesis significance testing. Acta Obstet. Gynecol. Scand. 101 (6), 624-627 (2022).","journal-title":"Acta Obstet. Gynecol. Scand"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.2337\/dc07-0816","type":"journal-article","article-title":"Symptoms of diabetes and their association with the risk and presence of diabetes: findings from the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD)","volume":"30","author":"Clark","year":"2007","unstructured":"Clark, N.G., Fox, K.M., Grandy, S., SHIELD Study Group. Symptoms of diabetes and their association with the risk and presence of diabetes: findings from the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD). Diabetes Care. 30 (11), 2868-2873 (2007).","journal-title":"Diabetes Care"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/dom.13605","type":"journal-article","article-title":"Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial","volume":"21","author":"Gu","year":"2019","unstructured":"Gu, T. et al. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial. Diabetes Obes. Metab. 21 (4), 939-948 (2019).","journal-title":"Diabetes Obes. Metab"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/andr.13296","type":"journal-article","article-title":"Saxagliptin alleviates erectile dysfunction through increasing stromal cell-derived factor-1 in diabetes mellitus","volume":"11","author":"Sun","year":"2023","unstructured":"Sun, T. et al. Saxagliptin alleviates erectile dysfunction through increasing stromal cell-derived factor-1 in diabetes mellitus. Andrology. 11 (2), 295-306 (2023).","journal-title":"Andrology"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","type":"journal-article","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","unstructured":"Parker, V.E.R. et al. Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nat. Metab. 5 (12), 2086-2093 (2023).","journal-title":"Nat. Metab"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","type":"journal-article","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","unstructured":"Johansson, L. et al. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes Obes. Metab. 22 (7), 1094-1101 (2020).","journal-title":"Diabetes Obes. Metab"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/mmr.2024.13219","type":"journal-article","article-title":"Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation mediating treatment options (review)","volume":"29","author":"Varra","year":"2024","unstructured":"Varra, F.N., Varras, M., Varra, V.K., Theodosis-Nobelos, P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation mediating treatment options (review). Mol. Med. Rep. 29 (6), 95 (2024).","journal-title":"Mol. Med. Rep"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2074610","DOI":"10.1155\/2021\/2074610","type":"journal-article","article-title":"The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"2021","author":"Guo","year":"2021","unstructured":"Guo, J. et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxid. Med. Cell. Longev. 2021, 2074610 (2021).","journal-title":"Oxid. Med. Cell. Longev"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","type":"journal-article","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","unstructured":"Krishnappa, M. et al. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc. Diabetol. 19 (1), 93 (2020).","journal-title":"Cardiovasc. Diabetol"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4093\/dmj.2021.0183","type":"journal-article","article-title":"Comparison of efficacy of glimepiride, alogliptin, and alogliptin-pioglitazone as the initial periods of therapy in patients with poorly controlled type 2 diabetes mellitus: an open-label, multicenter, randomized, controlled study","volume":"46","author":"Kim","year":"2022","unstructured":"Kim, H.J. et al. Comparison of efficacy of glimepiride, alogliptin, and alogliptin-pioglitazone as the initial periods of therapy in patients with poorly controlled type 2 diabetes mellitus: an open-label, multicenter, randomized, controlled study. Diabetes Metab. J. 46 (5), 689-700 (2022).","journal-title":"Diabetes Metab. J"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12967-024-05274-9","type":"journal-article","article-title":"Lipidomic studies revealing serological markers associated with the occurrence of retinopathy in type 2 diabetes","volume":"22","author":"He","year":"2024","unstructured":"He, M. et al. Lipidomic studies revealing serological markers associated with the occurrence of retinopathy in type 2 diabetes. J. Transl. Med. 22 (1), 448 (2024).","journal-title":"J. Transl. Med"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.advnut.2022.10.002","type":"journal-article","article-title":"Healthy plant-based diets improve dyslipidemias, insulin resistance, and inflammation in metabolic syndrome. A narrative review","volume":"14","author":"Thomas","year":"2023","unstructured":"Thomas, M.S., Calle, M., Fernandez, M.L. Healthy plant-based diets improve dyslipidemias, insulin resistance, and inflammation in metabolic syndrome. A narrative review. Adv. Nutr. 14 (1), 44-54 (2023).","journal-title":"Adv. Nutr"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3390\/biomedicines10092306","type":"journal-article","article-title":"Dipeptidyl peptidase 4 (DPP4) as a novel adipokine: role in metabolism and fat homeostasis","volume":"10","author":"Barchetta","year":"2022","unstructured":"Barchetta, I., Cimini, F.A., Dule, S., Cavallo, M.G. Dipeptidyl peptidase 4 (DPP4) as a novel adipokine: role in metabolism and fat homeostasis. Biomedicines. 10 (9), 2306 (2022).","journal-title":"Biomedicines"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijms26010040","type":"journal-article","article-title":"Evaluation of selected pro- and anti-inflammatory adipokines in colostrum from mothers with gestational diabetes mellitus","volume":"26","author":"Lis-Kuberka","year":"2024","unstructured":"Lis-Kuberka, J., Berghausen-Mazur, M., Orczyk-Pawi\u0142owicz, M. Evaluation of selected pro- and anti-inflammatory adipokines in colostrum from mothers with gestational diabetes mellitus. Int. J. Mol. Sci. 26 (1), 40 (2024).","journal-title":"Int. J. Mol. Sci"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-019-0455-5","type":"journal-article","article-title":"Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes","volume":"11","author":"Zheng","year":"2019","unstructured":"Zheng, L.Y., Xu, X., Wan, R.H., Xia, S., Lu, J., Huang, Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol. Metab. Syndr. 11, 60 (2019).","journal-title":"Diabetol. Metab. Syndr"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/dc14-2775","type":"journal-article","article-title":"Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD","volume":"38","author":"Belalcazar","year":"2015","unstructured":"Belalcazar, L.M. et al. Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD. Diabetes Care. 38 (8), 1544-1550 (2015).","journal-title":"Diabetes Care"},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2337\/dc08-1625","type":"journal-article","article-title":"Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts","volume":"32","author":"Chen","year":"2009","unstructured":"Chen, B.H. et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 32 (2), 329-334 (2009).","journal-title":"Diabetes Care"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/biomedicines12050983","type":"journal-article","article-title":"Chemerin levels in individuals with type 2 diabetes and a normal weight versus individuals with type 2 diabetes and obesity: an observational, cross-sectional study","volume":"12","author":"Mukherji","year":"2024","unstructured":"Mukherji, A.B. et al. Chemerin levels in individuals with type 2 diabetes and a normal weight versus individuals with type 2 diabetes and obesity: an observational, cross-sectional study. Biomedicines. 12 (5), 983 (2024).","journal-title":"Biomedicines"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1365162","DOI":"10.1155\/2019\/1365162","type":"journal-article","article-title":"Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity","volume":"2019","author":"Babenko","year":"2019","unstructured":"Babenko, A.Y. et al. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. J. Diabetes Res. 2019, 1365162 (2019).","journal-title":"J. Diabetes Res"},{"issue":"18","key":"ref52","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","type":"journal-article","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","unstructured":"Lundgren, J.R. et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N. Engl. J. Med. 384 (18), 1719-1730 (2021).","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.drudis.2021.11.001","type":"journal-article","article-title":"Obesity and insulin resistance: pathophysiology and treatment","volume":"27","author":"Tong","year":"2022","unstructured":"Tong, Y., Xu, S., Huang, L., Chen, C. Obesity and insulin resistance: pathophysiology and treatment. Drug Discov. Today. 27 (3), 822-830 (2022).","journal-title":"Drug Discov. Today"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70462\/saxagliptin-combined-with-liraglutide-vs-saxagliptin-alone-on","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:19:39Z","timestamp":1792585179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70462\/saxagliptin-combined-with-liraglutide-vs-saxagliptin-alone-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":53,"journal-issue":{"issue":"233","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70462","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}